JIB-04 | NSC 693627 | CAS#199596-05-9 | 199596-24-2 | Histone demethylase inhibitor

MedKoo Cat#: 406601 | Name: JIB-04

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JIB-04, also known as NSC 693627, is a Jumonji histone demethylase inhibitor. JIB-04 selectively blocks cancer cell growth in vitro and diminishes tumor growth in H358 and A549 mouse xenograft models in vivo. JIB-04 can prolong survival in a mouse model of breast cancer.

Chemical Structure

JIB-04

CAS#199596-05-9

Theoretical Analysis

MedKoo Cat#: 406601

Name: JIB-04

CAS#: 199596-05-9

Chemical Formula: C17H13ClN4

Exact Mass: 308.0829

Molecular Weight: 308.77

Elemental Analysis: C, 66.13; H, 4.24; Cl, 11.48; N, 18.15

Price and Availability

Size	Price	Availability
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,250.00	2 Weeks
1g	USD 3,450.00	2 Weeks
2g	USD 4,750.00	2 Weeks
5g	USD 6,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

199596-05-9 (JIB04) 199596-24-2 (JIB04 Z-isomer)

Synonym

JIB04; JIB-04; JIB 04; NSC 693627; NSC-693627; NSC 693627.

IUPAC/Chemical Name

(E)-5-chloro-2-(2-(phenyl(pyridin-2-yl)methylene)hydrazinyl)pyridine

InChi Key

YHHFKWKMXWRVTJ-OQKWZONESA-N

InChi Code

InChI=1S/C17H13ClN4/c18-14-9-10-16(20-12-14)21-22-17(13-6-2-1-3-7-13)15-8-4-5-11-19-15/h1-12H,(H,20,21)/b22-17+

SMILES Code

ClC1=CN=C(N/N=C(C2=CC=CC=C2)/C3=NC=CC=C3)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

In vitro activity:

Compared with DMSO-treated controls, all the JIB-04-treated HCC cells showed increased G1-phase subpopulations and decreased G2/M-phase subpopulations (Figure 1B), suggesting the occurrence of G1/S arrest in JIB-04-treated HCC cells. Thus, these data suggested that the reduced cell viability in JIB-04-treated HCC cells might be partly caused by JIB-04-induced cell cycle defects. Reference: Int J Mol Sci. 2022 Jul 11;23(14):7657. https://pubmed.ncbi.nlm.nih.gov/35887001/

In vivo activity:

JIB-04 administration also ameliorated the damage of GI epithelium in TGEV-infected animals (Fig. 5D), with fewer viral antigen-positive cells (Fig. S5D). Taken together, these data demonstrate in vivo antiviral activity of JIB-04 against a porcine coronavirus. Reference: mBio. 2022 Jan 18;13(1):e0337721. https://pubmed.ncbi.nlm.nih.gov/35038906/

	Solvent	mg/mL	mM
Solubility
	DMF	20.0	64.77
	DMSO	37.0	119.73
	Ethanol	1.5	4.86

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 308.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lee J, Kim JS, Cho HI, Jo SR, Jang YK. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells. Int J Mol Sci. 2022 Jul 11;23(14):7657. doi: 10.3390/ijms23147657. PMID: 35887001; PMCID: PMC9322929. 2. He Y, Yi X, Zhang Z, Luo H, Li R, Feng X, Fang ZM, Zhu XH, Cheng W, Jiang DS, Zhao F, Wei X. JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cells. Clin Epigenetics. 2022 Aug 13;14(1):101. doi: 10.1186/s13148-022-01321-8. PMID: 35964071; PMCID: PMC9375951. 3. Son J, Huang S, Zeng Q, Bricker TL, Case JB, Zhou J, Zang R, Liu Z, Chang X, Darling TL, Xu J, Harastani HH, Chen L, Gomez Castro MF, Zhao Y, Kohio HP, Hou G, Fan B, Niu B, Guo R, Rothlauf PW, Bailey AL, Wang X, Shi PY, Martinez ED, Brody SL, Whelan SPJ, Diamond MS, Boon ACM, Li B, Ding S. JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. mBio. 2022 Jan 18;13(1):e0337721. doi: 10.1128/mbio.03377-21. Epub ahead of print. PMID: 35038906; PMCID: PMC8764536. 4. Parrish JK, McCann TS, Sechler M, Sobral LM, Ren W, Jones KL, Tan AC, Jedlicka P. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. Oncotarget. 2018 Sep 4;9(69):33110-33123. doi: 10.18632/oncotarget.26011. PMID: 30237855; PMCID: PMC6145692.

In vitro protocol:

In vivo protocol:

1. Son J, Huang S, Zeng Q, Bricker TL, Case JB, Zhou J, Zang R, Liu Z, Chang X, Darling TL, Xu J, Harastani HH, Chen L, Gomez Castro MF, Zhao Y, Kohio HP, Hou G, Fan B, Niu B, Guo R, Rothlauf PW, Bailey AL, Wang X, Shi PY, Martinez ED, Brody SL, Whelan SPJ, Diamond MS, Boon ACM, Li B, Ding S. JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. mBio. 2022 Jan 18;13(1):e0337721. doi: 10.1128/mbio.03377-21. Epub ahead of print. PMID: 35038906; PMCID: PMC8764536. 2. Parrish JK, McCann TS, Sechler M, Sobral LM, Ren W, Jones KL, Tan AC, Jedlicka P. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. Oncotarget. 2018 Sep 4;9(69):33110-33123. doi: 10.18632/oncotarget.26011. PMID: 30237855; PMCID: PMC6145692.

1: Van Rechem C, Black JC, Boukhali M, Aryee MJ, Graslund S, Haas W, Benes CH, Whetstine JR. Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis. Cancer Discov. 2015 Jan 6. pii: CD-14-1326. [Epub ahead of print] PubMed PMID: 25564516. 2: Sekar TV, Foygel K, Gelovani JG, Paulmurugan R. Genetically Encoded Molecular Biosensors To Image Histone Methylation in Living Animals. Anal Chem. 2014 Dec 24. [Epub ahead of print] PubMed PMID: 25506787. 3: Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, Ruiz J, Bruick R, PeÃ±a-Llopis S, Xu J, Babinski DJ, Frantz DE, Brekken RA, Quinn AM, Simeonov A, Easmon J, Martinez ED. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 2013;4:2035. doi: 10.1038/ncomms3035. Erratum in: Nat Commun. 2013;4:2639. PubMed PMID: 23792809; PubMed Central PMCID: PMC3724450.